FDA allows emergency use of Roche’s Actemra for Covid-19
The indication is for intravenous use of the drug in both adult and paediatric patients aged two years and above who are on systemic corticosteroids and need supplemental
REGENXBIO has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) related to its biologics licence application (BLA) for RGX-121 (clemidsogene lanparvovec) to treat mucopolysaccharidosis II (MPS II), also called Hunter syndrome.
Arrowhead Pharmaceuticals has signed a global collaboration and license agreement with Horizon Therapeutics for the development of RNA interference (RNAi) therapeutic, ARO-XDH. ARO-XDH is a discovery-stage investigational RNAi